Titre
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Ter Haar, N.
Auteure/Auteur
Lachmann, H.
Auteure/Auteur
Özen, S.
Auteure/Auteur
Woo, P.
Auteure/Auteur
Uziel, Y.
Auteure/Auteur
Modesto, C.
Auteure/Auteur
Koné-Paut, I.
Auteure/Auteur
Cantarini, L.
Auteure/Auteur
Insalaco, A.
Auteure/Auteur
Neven, B.
Auteure/Auteur
Hofer, M.
Auteure/Auteur
Rigante, D.
Auteure/Auteur
Al-Mayouf, S.
Auteure/Auteur
Touitou, I.
Auteure/Auteur
Gallizzi, R.
Auteure/Auteur
Papadopoulou-Alataki, E.
Auteure/Auteur
Martino, S.
Auteure/Auteur
Kuemmerle-Deschner, J.
Auteure/Auteur
Obici, L.
Auteure/Auteur
Iagaru, N.
Auteure/Auteur
Simon, A.
Auteure/Auteur
Nielsen, S.
Auteure/Auteur
Martini, A.
Auteure/Auteur
Ruperto, N.
Auteure/Auteur
Gattorno, M.
Auteure/Auteur
Frenkel, J.
Auteure/Auteur
Contributrices/contributeurs
Kondi, A.
De Cunto, C.
Espada, G.
Russo, R.
Amaryan, G.
Boros, C.
Wouters, C.
de Oliveira, S.K.
Borzutzky, A.
Jelusic-Drazic, M.
Dolezalova, P.
Herlin, T.
Desjonqueres, M.
Djeddi, D.
Hentgen, V.
Darce, M.
Ioseliani, M.
Berendes, R.
Horneff, G.
Jansson, A.
Minden, K.
Schwarz, T.
Trauzeddel, R.
Kanakoudi Tsakalidou, F.
Vougiouka, O.
Constantin, T.
Rao, A.P.
Brik, R.
Harel, L.
Alessio, M.
Breda, L.
Cimaz, R.
Consolini, R.
Fabio, G.
Garozzo, R.
Lepore, L.
Manna, R.
Meini, A.
Olivieri, A.N.
Stanevicha, V.
Rusoniene, S.
Hoppenreijs, E.
Al-Abrawi, Sy
Nikishina, I.
Sewairi, W.M.
Susic, G.
Ciznar, P.
Avcin, T.
Anton, J.
Bou, R.
Merino, R.
Elorduy, M.J.
Fasth, A.
Aksu, G.
Demirkaya, E.
Groupes de travail
Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects
Liens vers les personnes
Liens vers les unités
ISSN
1468-2060
Statut éditorial
Publié
Date de publication
2013-05
Volume
72
Numéro
5
Première page
678
Dernière page/numéro d’article
685
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication Status: ppublish
Publication Status: ppublish
Résumé
To evaluate the response to treatment of autoinflammatory diseases from an international registry and an up-to-date literature review.
The response to treatment was studied in a web-based registry in which clinical information on anonymised patients with autoinflammatory diseases was collected retrospectively as part of the Eurofever initiative. Participating hospitals included paediatric rheumatology centres of the Paediatric Rheumatology International Trial Organisation network and adult centres with a specific interest in autoinflammatory diseases. The following diseases were included: familial Mediterranean fever (FMF), cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF)-receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), pyogenic arthritis pustulosis acne (PAPA) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), NLRP12-related periodic fever and periodic fever aphthosis pharyngitis adenitis (PFAPA) syndrome. Cases were independently validated by experts for each disease. A literature search regarding treatment of the abovementioned diseases was also performed using Medline and Embase.
22 months from the beginning of the enrolment, complete information on 496 validated patients was available. Data from the registry in combination with evidence from the literature confirmed that colchicine is the treatment of choice for FMF and IL-1 blockade for DIRA and CAPS. Corticosteroids on demand probably represent a valid therapeutic strategy for PFAPA, but also for MKD and TRAPS. Patients with poorly controlled MKD, TRAPS, PAPA or FMF may benefit from IL-1 blockade; anti-TNF treatment may represent a possible valuable alternative.
In the absence of high-grade evidence, these results could serve as a basis for therapeutic guidelines and to identify candidate drugs for future therapeutic trials.
The response to treatment was studied in a web-based registry in which clinical information on anonymised patients with autoinflammatory diseases was collected retrospectively as part of the Eurofever initiative. Participating hospitals included paediatric rheumatology centres of the Paediatric Rheumatology International Trial Organisation network and adult centres with a specific interest in autoinflammatory diseases. The following diseases were included: familial Mediterranean fever (FMF), cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF)-receptor associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), pyogenic arthritis pustulosis acne (PAPA) syndrome, deficiency of interleukin-1 receptor antagonist (DIRA), NLRP12-related periodic fever and periodic fever aphthosis pharyngitis adenitis (PFAPA) syndrome. Cases were independently validated by experts for each disease. A literature search regarding treatment of the abovementioned diseases was also performed using Medline and Embase.
22 months from the beginning of the enrolment, complete information on 496 validated patients was available. Data from the registry in combination with evidence from the literature confirmed that colchicine is the treatment of choice for FMF and IL-1 blockade for DIRA and CAPS. Corticosteroids on demand probably represent a valid therapeutic strategy for PFAPA, but also for MKD and TRAPS. Patients with poorly controlled MKD, TRAPS, PAPA or FMF may benefit from IL-1 blockade; anti-TNF treatment may represent a possible valuable alternative.
In the absence of high-grade evidence, these results could serve as a basis for therapeutic guidelines and to identify candidate drugs for future therapeutic trials.
Sujets
PID Serval
serval:BIB_82A5BAE9F71A
PMID
Date de création
2013-05-03T18:34:11.812Z
Date de création dans IRIS
2025-05-20T23:38:03Z